Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $28.5 million.

  • Neurocrine Biosciences' Non Operating Income rose 3834.95% to $28.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $86.3 million, marking a year-over-year increase of 20213.02%. This contributed to the annual value of $86.3 million for FY2025, which is 20213.02% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Non Operating Income stood at $28.5 million, which was up 3834.95% from $52.8 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Non Operating Income ranged from a high of $52.8 million in Q3 2025 and a low of -$64.8 million during Q1 2024
  • For the 4-year period, Neurocrine Biosciences' Non Operating Income averaged around $4.0 million, with its median value being $6.5 million (2024).
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 69449.54% in 2024, then skyrocketed by 71230.77% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Non Operating Income (Quarter) stood at -$14.0 million in 2021, then skyrocketed by 442.14% to $47.9 million in 2023, then crashed by 56.99% to $20.6 million in 2024, then soared by 38.35% to $28.5 million in 2025.
  • Its last three reported values are $28.5 million in Q4 2025, $52.8 million for Q3 2025, and $13.9 million during Q2 2025.